Jackson, Dr Andrew
MA MD MRCP FRCR
Speciality
Clinical oncology
Sub-speciality
GI cancers, lung cancer, skin cancer
Training and education
Undergraduate training 1989-1995 : University of Cambridge and St George’s Hospital Medical School
MRCP 1998
Oncology Training 1999-2006: pan-Thames training scheme
FRCR 2003
MD 2003-2005: Royal Marsden Hospital/Institute of Cancer Research
Experience
Dr Jackson has worked for Southampton University Hospitals Trust since October 2010.
He gained his CCST in Clinical Oncology in 2006 and took a post as a Clinical Lecturer and Hon. Consultant Oncologist at The University of Manchester/Christie Hospital specialising in upper GI cancers, with additional academic interests in Image Guided Radiotherapy (IGRT) and imaging.
In 2010 he moved to SUHT with 2 days per week at North Hampshire Hospital.
He is continuing to pursue his research interest in upper GI cancers.
Key achievements
Principal Investigator, ROCOCO: Radiotherapy and Olaparib in Combination for Oesophageal Cancer. Phase 1 dose escalation study. Awarded funding by CRUK New Agents Committee January 2011
Principal investigator, Christie Hospital, Manchester: PACER (Locally Advanced pancreatic cancer: Phase II study of Cetuximab and 3-D conformal Image Guided Radiotherapy). Three centre NCRN badged study
Co-investigator, Christie Hospital, Manchester: ‘A real time visual feedback device for reducing patient movement during radiotherapy’, NIHR New and Emerging Applications of Technology (NEAT) award 2008
Principal investigator Christie Hospital, Manchester: DCE-MRI in oesophageal cancer: a pilot study. University of Manchester Magnetic Resonance Imaging Facility.
Member of NCRI CTRad Workstream 3 (Phase III trials) (formerly Clinical and Translational Radiotherapy Research Working Group)
Key awards and prizes
Rohan Williams Medal for FRCR 2003
Research
Recent publications include:
A Saleem, A. Jackson , S Mukherjee, N Stones, T Crosby, D Tait, P Price. Radiotherapy in the Management of Unresectable Locally Advanced Pancreatic Cancer: a Survey of the Current UK Practice of Clinical Oncologists. Clin Oncol (R Coll Radiol). 2010 May;22(4):257-60
MT Guerrero Urbano, J Staffurth , A. Norman,, FM Buffa, A Jackson, EJ Adams, V Hansen, C Clark, L Miles, H McNair, CM Nutting, C Parker, V Khoo, R Eeles, R Huddart, A Horwich, DP Dearnaley. Intensity Modulated Radiotherapy (IMRT) allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: Results of a phase 1 dose escalation study. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):236-44
ASN Jackson, P Jain, GR Watkins, , GA Whitfield, MM Green, J Valle, MB Taylor, C Dickinson, PM Price, A Saleem. Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. Clin Oncol (R Coll Radiol) 2010 Sep;22(7):570-7
ASN Jackson, SA Reinsberg, SA Sohaib, EM Charles-Edwards, SG Jhavar, TJ Christmas, AC Thompson, MJ Bailey, CM Corbishley, C Fisher, MO Leach, DP Dearnaley. Dynamic Contrast Enhanced MRI for Prostate Cancer Localisation. Br J Radiol. 2009 Feb;82(974):148-56.
Raj Sripadam, Julie Stratford, Ann M. Henry, Andrew Jackson, Chris J. Moore, Pat Price. Rectal motion can reduce CTV coverage and increase rectal dose during prostate radiotherapy: a daily cone beam CT study. Radiother Oncol. 2009;90(3):312-317